Leo S. Gomez, Ph.D.

Director of Research

Technology Commercialization International, Inc.

Albuquerque, NM, USA

Technology Commercialization International, Inc. (TCI), founded in Albuquerque, NM in 1994, is a privately held corporation providing innovative solutions in nuclear medicine, therapeutic technologies, and diagnostic imaging systems worldwide. TCI works closely with key U.S. National Laboratories to collaborate with leading institutions of the Russian Academy of Sciences and other research institutions in the Former Soviet Union. TCI holds majority ownership in US-Russian Isotopes, LLC, a joint venture with the Kurchatov Institute in Moscow. TCI owns eleven U.S. patents with additional international patents pending. TCI’s business lines include a) non-invasive diagnostic tomographic devices, b) medical radioisotopes, and c) hardware systems to produce medical radioisotopes.

TCI’s operations in the Russian Federation include programs with the following institutions:

• Russian Research Center-Kurchatov Institute, Moscow
• Institute for Nuclear Research, Troitsk
• Institute of Radioengineering and Electronics, Moscow
• Ural State Technical University, Ekaterinburg
• Institute of Nuclear Physics of the Republic of Kazakhstan
• Russian State Scientific Center, Moscow

The Technology Center for Cancer Research (TCCR), an affiliated, independent non-profit 501 (c) (3) tax exempt institute is conducting clinical trials for the Centillion^TM breast cancer detection device developed in collaboration with a Russian institute, and based on 3-dimensional electrical impedance tomography (3D EIT). TCCR will also conduct clinical trials and research in other areas of cancer detection.

TCI’s experiences in international collaborations will be discussed.